Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies
Martin Gartland
(1)
,
Michael Aboud
(2)
,
Josep M Llibre
,
Chien-Ching Hung
(3)
,
Cynthia Brinson
(4)
,
Francesco Castelli
(5)
,
Pierre-Marie Girard
(6, 7)
,
Lesley P Kahl
(2)
,
Elizabeth A Blair
(1)
,
Kostas Angelis
(8)
,
Brian Wynne
(1)
,
Kati Vandermeulen
(9)
,
Mark Underwood
(1)
,
Kim Smith
(1)
1
ViiV Healthcare US
2 ViiV Healthcare [Brentford, UK]
3 NTU - National Taiwan University [Taiwan]
4 Central Texas Clinical Research
5 UniBs - Università degli Studi di Brescia = University of Brescia
6 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
7 CHU Saint-Antoine [AP-HP]
8 GSK - GlaxoSmithKline
9 Janssen Pharmaceutica N.V. [Beerse, Belgium]
2 ViiV Healthcare [Brentford, UK]
3 NTU - National Taiwan University [Taiwan]
4 Central Texas Clinical Research
5 UniBs - Università degli Studi di Brescia = University of Brescia
6 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
7 CHU Saint-Antoine [AP-HP]
8 GSK - GlaxoSmithKline
9 Janssen Pharmaceutica N.V. [Beerse, Belgium]